专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明公开

EP1739431A1 METHOD OF JUDGING NON-ALCOHOLIC STEATOHEPATITIS 审中-公开
标题翻译： VERFAHREN ZUR BEURTEILUNG NICHTALKOHOLISCHER STEATOHEPATITIS
公开(公告)号：EP1739431A1
公开(公告)日：2007-01-03
申请号：EP05733999.6
申请日：2005-04-25
申请人： Ajinomoto Co., Inc.
发明人： TAKATSUKI, Fumihiko, c/o AJINOMOTO CO., INC. , UENO, Takato , SATA, Michio
IPC分类号： G01N33/92 , G01N33/15 , G01N33/50
CPC分类号： G01N33/92 , G01N2800/08 , Y10T436/204165
摘要： According to the present invention, phospholipids of the peripheral blood and fatty acid compositions thereof are measured. Especially, the amounts of phosphatidylserine/phosphatidylinositol and phosphatidyl choline, and fatty acid compositions in the peripheral blood are measured. Thus, the present invention can provide a method for evaluating therapeutic agents of NASH that are useful in the patients with NASH, a method of judging NASH, and the therapeutic agents thereof.
摘要翻译：根据本发明，测定外周血的磷脂及其脂肪酸组成。特别地，测量了磷脂酰丝氨酸/磷脂酰肌醇和磷脂酰胆碱的量，以及外周血中的脂肪酸组成。因此，本发明可以提供一种用于评价NASH的治疗剂的方法，其用于NASH患者，判断NASH的方法及其治疗剂。

42. 发明公开

EP1576012A4 MONOCLONAL ANTIBODY AGAINST ASIALO ALPHA 1-ACID GLYCOPROTEIN, IMMUNOCHROMATOGRAPHIC STRIP COMPRISING THE MONOCLONAL ANTIBODY, AND METHOD FOR DIAGNOSING LIVER DISEASES USING THE IMMUNOCHROMATOGRAPHIC STRIP 审中-公开
标题翻译：反对去唾液酸的α1酸性糖蛋白免疫层析单克隆抗体单克隆抗体和方法诊断肝病使用免疫层析
公开(公告)号：EP1576012A4
公开(公告)日：2006-05-31
申请号：EP03779033
申请日：2003-12-27
申请人： NEOBIODIGM CO LTD
发明人： CHUNG TAI-WHA , SONG EUN-YOUNG , KANG JI-HYUN , KIM KYOUNG-A , LEE EUN-YOUNG , CHOE YONG-KYUNG
IPC分类号： C07K16/18 , C07K16/28 , G01N33/558 , G01N33/68 , C07K16/34 , C12N5/20 , G01N33/543
CPC分类号： G01N33/6893 , C07K16/18 , C07K16/28 , G01N33/558 , G01N2400/02 , G01N2800/08 , G01N2800/085
摘要： The present invention relates to a method for diagnosing a liver disease rapidly in an early stage. More particularly, the present invention relates to a monoclonal antibody against asialo alpha 1-acid glycoprotein; a method for diagnosing a liver disease which evaluates asialo alpha 1-acid glycoprotein in a test sample by using said monoclonal antibody; and an diagnostic strip for immunochromatography composed of said monoclonal antibody against asialo alpha 1-acid glycoprotein and Ricinus communis agglutinin (RCA). The diagnostic device of the present invention is convenient to measure the concentration of asialo alpha 1-acid glycoprotein and to diagnose a liver disease rapidly.

43. 发明公开

EP1577385A1 MARKER PROTEINS FOR DIAGNOSING LIVER DISEASE AND METHOD OF DIAGNOSING LIVER DISEASE USING THE SAME 有权
标题翻译：标记蛋白肝病和方法，用于诊断肝脏疾病的诊断THAT
公开(公告)号：EP1577385A1
公开(公告)日：2005-09-21
申请号：EP03786267.9
申请日：2003-12-24
申请人： NITTO BOSEKI CO., LTD.
发明人： NOMURA, Fumio, c/o Chiba Univ. school of Medicine , SOGAWA, Kazuyuki, c/o Chiba Univ. school of Med. , TOMONAGA, Takeshi, c/o Chiba Univ. school of Med. , OCHIAI, Takenori, c/o Chiba Univ. school of Med. , SHIMADA, Hideaki, c/o Chiba Univ. school of Med. , OHASHI, Tatsuya, c/o Nittobo Biochem. Laboratory , KATAYAMA, Katsuhiro, c/o Nittobo Medical Dev. Ctr.
IPC分类号： C12N15/09 , C07K14/47 , C07K14/75 , C07K14/775 , G01N27/62 , G01N27/64 , G01N33/53
CPC分类号： G01N33/6893 , G01N2333/75 , G01N2333/775 , G01N2800/08
摘要： Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.

44. 发明公开

EP1410803A1 MIA-2 Proteine 失效转让
标题翻译： MIA-2蛋白
公开(公告)号：EP1410803A1
公开(公告)日：2004-04-21
申请号：EP03023591.5
申请日：2003-10-16
申请人： Scil proteins GmbH
发明人： Bosserhoff, Anja , Hellerbrand, Claus , Büttner, Reinhard
IPC分类号： A61K38/17 , C07K14/47 , C07K16/18 , C12Q1/68 , C12N15/11 , A01K67/027 , C12N5/10
CPC分类号： A61K35/407 , A61K38/00 , C07K14/47 , G01N33/6893 , G01N2800/08 , G01N2800/085 , Y02A50/473
摘要： Die vorliegende Erfindung betrifft das humane und murine MIA-2 Protein sowie die diese Proteine kodierenden Nukleinsäuren. Die Erfindung betrifft weiterhin Antikörper und Aptamere, die an diese Proteine binden sowie pharmazeutische und diagnostische Zusammensetzungen und deren Verwendung in der Therapie und Diagnose von Leberzirrhose, Leberfibrose oder von Lebertumoren/-Metastasen. Die vorliegende Erfindung betrifft weiterhin ein Verfahren zur Herstellung einer Organkultur sowie deren Verwendung zur Blutreinigung .
摘要翻译：分别由序列（1）和（27）编码的人或鼠MIA-2（黑素瘤抑制活性-2）蛋白（A）包含1626和1628bp，其变体具有一个或多个取代，插入和/或删除是新的。分别由1626和1628bp的序列（1）和（27）编码的人或鼠MIA-2（黑素瘤抑制活性-2）蛋白（A）及其变体具有一个或多个取代，插入和/或删除是新的。变体（a）在中度严格条件下与（1）或（27）杂交并编码具有MIA-2活性的蛋白质，或（b）在遗传密码范围内是退化的，并且编码与（1）和（ 27）或其功能等同物。（A）不完全由（1）的碱1-354或（27）的1-357或其片段编码。还包括以下独立索赔：（1）隔离（1）和（27）及其变体，如上所述; （2）MIA-2启动子，其包含3090bp的序列（人）; （3）（i）是项目（1）和（2）或（ii）的核酸（NA2）的转录产物（TP）的核酸（NA1）可以在中等严格条件下选择性地结合TP，特别是反义RNA或DNA; （4）与NA2杂交的DNA或RNA探针; （5）包含NA1或NA2的载体; （6）用（5）载体转化的宿主细胞; （7）针对（A）的表位的抗体或适体; （8）其中MIA-2序列失活的转基因哺乳动物，优选条件地或其中基因组含有一种或多种NA2的转基因哺乳动物; （9）用于诊断肝损伤的离体方法，用于检测增加的肝脏合成能力或用于检测感染，炎性或风湿性疾病的急性期; （10）通过使哺乳动物肝细胞与MIA-2蛋白质接触来制备器官培养物; 和（11）通过方法（10）生产的器官培养物。

45. 发明公开

EP3310901A1 IN VITRO PRODUCTION OF CHOLANGIOCYTES 有权
标题翻译：体外生产胆管细胞
公开(公告)号：EP3310901A1
公开(公告)日：2018-04-25
申请号：EP16732328.6
申请日：2016-06-21
申请人： Cambridge Enterprise Limited
发明人： VALLIER, Ludovic , SAMPAZIOTIS, Fotis , HANNAN, Nicholas
IPC分类号： C12N5/071 , A61K35/413 , G01N33/50
CPC分类号： C12N5/0672 , A61K35/413 , A61P1/16 , C12N5/067 , C12N5/0676 , C12N5/0679 , C12N2501/11 , C12N2501/115 , C12N2501/119 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/36 , C12N2501/385 , C12N2501/415 , C12N2501/42 , C12N2501/999 , C12N2503/02 , C12N2506/14 , C12N2506/22 , C12N2506/45 , C12N2513/00 , C12N2533/90 , G01N33/5008 , G01N33/5044 , G01N33/5091 , G01N2800/08
摘要： This invention relates to the efficient generation of cholangiocyte progenitor (CP) cells. Foregut stem cells (FSCs) are cultured in a hepatic induction medium comprising bone morphogenetic protein (BMP) and a TGFβ signalling inhibitor to produce a population of hepatoblasts. The hepatoblasts are then cultured in a biliary induction medium comprising fibroblast growth factor (FGF), retinoic acid and a TGFβ ligand to produce a population of cholangiocyte progenitors (CPs). The cholangiocyte progenitors (CPs) may be matured into cholangiocyte-like cells (CLCs) that display functional properties of Common Bile Duct (CBD) cholangiocytes. Methods, kits, cell populations and uses of these cell populations are provided.

46. 发明公开

EP3129787A1 PROGNOSTIC TESTS FOR HEPATIC DISORDERS 有权转让
标题翻译： PROGNOSTISCHE测试FÜRLEBERSTÖRUNGEN
公开(公告)号：EP3129787A1
公开(公告)日：2017-02-15
申请号：EP15713925.4
申请日：2015-04-08
申请人： Centre Hospitalier Universitaire D'angers , Université d'Angers
发明人： CALÈS, Paul , BOURSIER, Jérôme , BERTRAIS, Sandrine
IPC分类号： G01N33/576 , G01N33/68
CPC分类号： G06F19/3437 , G01N33/576 , G01N33/6893 , G01N2800/08 , G06F17/18 , G06F19/00 , G06F19/3431 , G16H50/30 , G16H50/50
摘要： The present invention relates to in vitro prognostic method for assessing the risk of death or of liver-related event in a subject, comprising: a. obtaining at least one, preferably at least 2, of the following variables from the subject: i. biomarkers measured in a sample from the subject; ii. clinical data; iii. binary markers; iv. blood test results; b. optionally obtaining at least one blood test result by univariate combination, preferably with a binary logistic regression, of the at least one variable obtained in step (a), said blood test not being a Fibrotest, c. obtaining at least one physical data from medical imaging or clinical measurement, preferably from elastometry, more preferably from Vibration Controlled Transient Elastography (VCTE), and d. mathematically combining in a multivariate time-dependent model - said at least one variable obtained in step (a) and/or said at least one blood test result obtained in step b); and - said at least one physical data, obtained in step (c) thereby obtaining a prognostic score.
摘要翻译：本发明涉及用于评估受试者的死亡风险或肝脏相关事件的体外预后方法，包括：a。从主题中获得至少一个，优选至少2个以下变量：i。在受试者样本中测量的生物标志物; II。临床资料; III。二进制标记 IV。血液检查结果; 湾任选地通过单因素组合（优选用二元逻辑回归）获得至少一个在步骤（a）中获得的至少一个变量的血液测试结果，所述血液测试不是Fibrotest，c。从医学成像或临床测量获得至少一个物理数据，优选地来自弹性测量，更优选地来自振动控制瞬态弹性成像（VCTE），以及d。在多变量时间依赖模型中数学组合 - 所述步骤（a）中获得的至少一个变量和/或步骤b）中获得的所述至少一个血液测试结果; 和 - 在步骤（c）中获得的至少一个物理数据，由此获得预后评分。

47. 发明公开

EP2938740A4 METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES 有权转让
标题翻译：方法的GALLENSÄUREHOMÖOSTASE的调节和治疗瘿酸病杂志
公开(公告)号：EP2938740A4
公开(公告)日：2016-11-30
申请号：EP13868063
申请日：2013-12-26
申请人： NGM BIOPHARMACEUTICALS INC
发明人： LING LEI , LUO JIAN
IPC分类号： C12P21/02 , C07K14/50
CPC分类号： A61K38/1825 , C07K14/50 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/92 , G01N2500/04 , G01N2800/04 , G01N2800/08
摘要： The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

48. 发明公开

EP2983693A4 Sept4/ARTS AS A TUMOR SUPPRESSOR IN THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF HEPATIC DISORDERS 审中-公开
标题翻译： SEPT4 / ARTS作为肿瘤抑制诊断，预后和治疗肝脏疾病的
公开(公告)号：EP2983693A4
公开(公告)日：2016-10-26
申请号：EP14782569
申请日：2014-04-07
申请人： UNIV CARMEL HAIFA ECONOMIC COR , UNIV ROCKEFELLER
发明人： LARISCH SARIT , STELLER HERMANN
IPC分类号： A61K38/17 , A61P1/16 , A61P35/00 , C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , A61K31/185 , A61K31/53 , A61K38/17 , C12Q2600/118 , C12Q2600/154 , G01N33/57438 , G01N33/576 , G01N2800/08 , G01N2800/085 , G01N2800/52 , G01N2800/54
摘要： The invention relates to methods for the diagnosis and prognosis of hepatic disorder and associated pathologies as well as of a solid proliferative disorder in a mammalian subject. More specifically, the methods of the invention are based on determining the expression, methylation of ARTS as well as histone trimethylation. The invention further provides therapeutic methods for treating said disorders.

49. 发明公开

EP2930515A1 Prognostic tests for hepatic disorders 审中-公开
标题翻译：预测测试费尔伯斯特伦根
公开(公告)号：EP2930515A1
公开(公告)日：2015-10-14
申请号：EP14163948.4
申请日：2014-04-08
申请人： UNIVERSITE D'ANGERS , Centre Hospitalier Universitaire d'Angers
发明人： Calès, Paul , Boursier, Jérôme , Bertrais, Sandrine
IPC分类号： G01N33/576 , G01N33/68
CPC分类号： G06F19/3437 , G01N33/576 , G01N33/6893 , G01N2800/08 , G06F17/18 , G06F19/00 , G06F19/3431 , G16H50/30 , G16H50/50
摘要： The present invention relates to in vitro prognostic method for assessing the risk of death or of liver-related event in a subject, comprising:
a. obtaining at least one, preferably at least 2, of the following variables from the subject:
i. biomarkers measured in a sample from the subject;
ii. clinical data;
iii. binary markers;
iv. blood test results;

b. optionally obtaining at least one blood test result by univariate combination, preferably with a binary logistic regression, of the at least one variable obtained in step (a), said blood test not being a Fibrotest,
c. obtaining at least one physical data from medical imaging or clinical measurement, preferably from elastometry, more preferably from Vibration Controlled Transient Elastography (VCTE), and
d. mathematically combining in a multivariate time-dependent model
- said at least one variable obtained in step (a) and/or said at least one blood test result obtained in step b); and
- said at least one physical data, obtained in step (c)

thereby obtaining a prognostic score.
摘要翻译：本发明涉及用于评估受试者的死亡风险或肝脏相关事件的体外预后方法，包括：a。从主题中获得至少一个，优选至少2个以下变量：i。在受试者样本中测量的生物标志物; II。临床资料; III。二进制标记 IV。血液检查结果; 湾任选地通过单因素组合（优选用二元逻辑回归）获得至少一个在步骤（a）中获得的至少一个变量的血液测试结果，所述血液测试不是Fibrotest，c。从医学成像或临床测量获得至少一个物理数据，优选地来自弹性测量，更优选地来自振动控制瞬态弹性成像（VCTE），以及d。在多变量时间依赖模型中数学组合 - 所述步骤（a）中获得的至少一个变量和/或步骤b）中获得的所述至少一个血液测试结果; 和 - 在步骤（c）中获得的至少一个物理数据，由此获得预后评分。

50. 发明公开

EP2923202A1 BIOMARKERS FOR THE IDENTIFICATION OF LIVER DAMAGE 审中-公开
标题翻译：生物识别器ZEN IDENTIFIZIERUNG VONLEBERSCHÄDEN
公开(公告)号：EP2923202A1
公开(公告)日：2015-09-30
申请号：EP13786591.1
申请日：2013-10-24
申请人： THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY d/b/a CAROLINAS HEALTHCARE SYSTEM
发明人： BONKOVSKY, Herbert L , FOUREAU, David , NORTON, H. James , STEUERWALK, Nury
IPC分类号： G01N33/50
CPC分类号： G01N33/6893 , G01N2333/49 , G01N2333/503 , G01N2333/523 , G01N2333/525 , G01N2333/54 , G01N2333/5406 , G01N2333/5409 , G01N2333/5412 , G01N2333/5425 , G01N2333/5434 , G01N2333/5437 , G01N2333/765 , G01N2800/08 , G01N2800/085 , G01N2800/52 , G01N2800/60
摘要： Methods and kits for characterizing liver damage in an individual are provided. The methods employ the use of immune analytes as biomarkers for detecting liver damage and predicting the likelihood that an individual suffering from liver damage will experience life-threatening liver failure. Concentration values for serum albumin and other identified immune analytes are obtained or determined from a blood sample taken from the individual. The obtained concentration values are then compared to corresponding concentrations from individuals having a healthy liver. By comparing the concentrations, an individual's likelihood of developing life-threatening liver failure and needing a liver transplant within a given time period (e.g., 6 months) can be identified.
摘要翻译：提供了用于表征个体肝损伤的方法和试剂盒。该方法采用免疫分析物作为检测肝损伤的生物标志物，并预测患有肝损伤的个体将会遇到危及生命的肝衰竭的可能性。从取自个体的血液样品获得或确定血清白蛋白和其他鉴定的免疫分析物的浓度值。然后将获得的浓度值与具有健康肝脏的个体的相应浓度进行比较。通过比较浓度，可以确定个体在给定时间段（例如6个月）内发展危及生命的肝衰竭和需要肝移植的可能性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式